论文部分内容阅读
目的 评价坎地沙坦酯治疗原发性轻中度高血压的临床疗效和安全性。方法 选择48例轻中度原发性高血压病人通过2周导入期后随机分入试验组和对照组各24例,按双盲、平行临床药理试验方法分别给予坎地沙坦酯和氯沙坦治疗。治疗4周后如不能有效控制血压,则将用药剂量加倍并维持到第8周末。检测患者治疗前和治疗后不同时间的血压、心率以及血常规、尿常规、肝、肾功能。记录用药期间可能发生的不良事件。结果 试验组和对照组降压显效率均为100%,治疗后2周末收缩压(SBP)和舒张压(DBP)均已明显降低。此后血压继续下降,与用药治疗前相比,用药8周末,试验组和对照组SBP分别下降20.3mmHg和16.4mmHg,DBP分别下降16.8 mmHg和16.1 mmHg。试验组1例病人服药期间出现中度头痛,1例病人感轻度胸闷和腹胀。两组血常规、肝、肾功能均正常。结论 坎地沙坦酯治疗原发性轻中度高血压疗效良好、服用安全。
Objective To evaluate the clinical efficacy and safety of candesartan cilexetil in the treatment of primary mild to moderate hypertension. Methods Forty-eight patients with mild-to-moderate essential hypertension were randomly divided into experimental group (24 cases) and control group (24 cases) after two-week induction period, and were treated with candesartan cilexetil and cisplatin Tan treatment. After 4 weeks of treatment, if the blood pressure can not be effectively controlled, the dosage will be doubled and maintained until the end of the 8th week. Blood pressure, heart rate, blood routine, urine routine, liver and kidney function were measured before and after treatment. Record the possible adverse events during the treatment. Results The effective rate of hypotension was 100% in test group and control group, SBP and DBP decreased significantly after 2 weeks of treatment. Blood pressure continued to decline. Compared with those before treatment, SBP of test group and control group decreased by 20.3 mmHg and 16.4 mmHg, respectively, and DBP decreased by 16.8 mmHg and 16.1 mmHg respectively. In the test group, 1 patient had moderate headache during medication and 1 patient had mild chest tightness and abdominal distension. Two groups of blood, liver and kidney function are normal. Conclusion Candesartan cilexetil treatment of primary mild to moderate hypertension is effective and safe to take.